Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07013201 · ClinicalTrials.gov registry record · Phase 2
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
A Phase 2 study of Palmoplantar Pustulosis, sponsored by LEO Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 20
- Study locations
NCT07013201: Recruiting Phase 2 study of Palmoplantar Pustulosis, sponsored by LEO Pharma.
NCT07013201 is a Phase 2 study of Palmoplantar Pustulosis that is actively recruiting participants, run by LEO Pharma. The registered enrollment target is 135 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07013201, a Phase 2 study of Palmoplantar Pustulosis, is actively recruiting participants, sponsored by LEO Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.
Conditions Studied
Interventions
- DRUG Delgocitinib cream
- DRUG Vehicle cream
Study Locations (20)
Other
- LEO Pharma Investigational Site - Bad Bentheim
- LEO Pharma Investigational Site - Dresden
- LEO Pharma Investigational Site - Göttingen
- LEO Pharma Investigational Site - Kiel
- LEO Pharma Investigational Site - Lübeck
Ontario
- LEO Pharma Investigational Site - Hamilton
- LEO Pharma Investigational Site - Hamilton
- LEO Pharma Investigational Site - Markham
- LEO Pharma Investigational Site - Waterloo
California
- LEO Pharma Investigational Site - Fountain Valley
Georgia
- LEO Pharma Investigational Site - Douglasville
Michigan
- LEO Pharma Investigational Site - West Bloomfield
New York
- LEO Pharma Investigational Site - Elmhurst
Ohio
- LEO Pharma Investigation Site - Mayfield Heights
Oregon
- LEO Pharma Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2026-12-14 |
| Phase | Phase 2 |
What NCT07013201 shows while recruiting
NCT07013201 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Palmoplantar Pustulosis appearing as the primary indexed condition, and to 2 interventions - of which Delgocitinib cream is the first listed.
NCT07013201 names 20 study sites across 13 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT07013201 about?
NCT07013201 is a clinical study titled "A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis". The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately...
What is the current status of trial NCT07013201?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2025-09-11. Estimated completion is 2026-12-14.
What conditions does trial NCT07013201 study?
This clinical trial studies the following conditions: Palmoplantar Pustulosis.
What interventions are being tested in trial NCT07013201?
The interventions under investigation include: Delgocitinib cream (DRUG), Vehicle cream (DRUG).
Who is sponsoring clinical trial NCT07013201?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07013201 being conducted?
This trial has 20 study locations across California, Georgia, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Palmoplantar Pustulosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07013201's enrollment target sits among peer trials
135 532nd of 2000 higher than 1,465 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI